Search Results | Cancer Research | American Association for Cancer Research

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Abstract 3242: The role of SERPINE1 in trametinib resistance in low-grade ovarian serous cancer cell line

Chun Wai Ng, Yvonne TM Tsang, David M. Gershenson, Kwong-Kwok Wong

Cancer Res (2022) 82 (12_Supplement): 3242.

DOI: https://doi.org/10.1158/1538-7445.AM2022-3242

Published: 15 June 2022

View article

Journal Articles

Abstract 3985: GDF15 expression level impacts the canonical pathways of the tumor microenvironment and ovarian tumors with wild-type p53 in response to chemotherapy

Daisy I. Izaguirre, Yvonne TM Tsang, Eucharist H. Kun, David M. Gershenson, Kwong-Kwok Wong

Cancer Res (2020) 80 (16_Supplement): 3985.

DOI: https://doi.org/10.1158/1538-7445.AM2020-3985

Published: 15 August 2020

View article

Journal Articles

Abstract CT020: Phase I dose escalation of olaparib (PARP inhibitor) and selumetinib (MEK Inhibitor) combination in solid tumors with Ras pathway alterations

Katherine C. Kurnit, Funda Meric-Bernstam, Kenneth Hess, Robert L. Coleman, Priya Bhosale, Katerina Savelieva, Filip Janku, David Hong, Aung Naing, Shubham Pant, Jordi Rodon, Timothy A. Yap, Anil K. Sood, Pamela T. Soliman, David M. Gershenson, Gordon B. Mills, Shannon N. Westin

Cancer Res (2019) 79 (13_Supplement): CT020.

DOI: https://doi.org/10.1158/1538-7445.AM2019-CT020

Published: 01 July 2019

View article

Journal Articles

Abstract 135: Immunosuppressive microenvironment in low-grade serous ovarian carcinoma

Kwong-Kwok Wong, David M. Gershenson

Cancer Res (2018) 78 (13_Supplement): 135.

DOI: https://doi.org/10.1158/1538-7445.AM2018-135

Published: 01 July 2018

View article

Journal Articles

Abstract CT-05: A phase II trial of selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum

John H. Farley, William E. Brady, Michael J. Birrer, Heather Lankes, Robert Coleman, Mark Morgan, Robert Mannel, Diane Yamada, David Mutch, William H. Rodgers, David M. Gershenson

Cancer Res (2012) 72 (8_Supplement): CT-05.

DOI: https://doi.org/10.1158/1538-7445.AM2012-CT-05

Published: 15 April 2012

View article

Journal Articles

Abstract 2784: Nutlin-3 induces cell cycle arrest in p53 wild-type ovarian carcinomas via upregulation of p21

Erin R. King, Lisa K. Mullany, David M. Gershenson, JoAnne S. Richards, Kwong Kwok Wong

Cancer Res (2012) 72 (8_Supplement): 2784.

DOI: https://doi.org/10.1158/1538-7445.AM2012-2784

Published: 15 April 2012

View article

Journal Articles

Abstract 5031: Insulin-like growth factor-1 (IGF-1) is upregulated in low-grade serous ovarian carcinoma

Erin R. King, Zhifei Zu, Yvonne T.M. Tsang-Lee, David M. Gershenson, Samuel C. Mok, Kwong-Kwok Wong

Cancer Res (2011) 71 (8_Supplement): 5031.

DOI: https://doi.org/10.1158/1538-7445.AM2011-5031

Published: 15 April 2011

View article

Journal Articles

Abstract 4288: Targeted therapy against aldehyde dehydrogenase in ovarian cancer

Charles N. Landen, Blake Goodman, Alpa M. Nick, Rebecca L. Stone, Pablo V. Meijia, Lance D. Miller, Nicolas B. Jennings, David M. Gershenson, Robert C. Bast, Robert L. Coleman, Gabriel Lopez-Berestein, Anil K. Sood

Cancer Res (2010) 70 (8_Supplement): 4288.

DOI: https://doi.org/10.1158/1538-7445.AM10-4288

Published: 15 April 2010

View article

Journal Articles

Abstract 2129A: Clinical implications of infrequent BRAF mutation in advanced stage low-grade ovarian serous carcinomas

Kwong-Kwok Wong, Yvonne TM Tsang, Michael T. Deavers, Samuel C. Mok, David M. Gershenson

Cancer Res (2010) 70 (8_Supplement): 2129A.

DOI: https://doi.org/10.1158/1538-7445.AM10-2129A

Published: 15 April 2010

View article

Journal Articles

Abstract 3298: Elf3 as negative regulation for epithelial-mesenchymal transition in ovarian cancer

Tsz-Lun Yeung, Kwong-Kwok Wong, Arthur Gutierrez-Hartmann, Joseph Kwong, William R. Welch, David M. Gershenson, Michael J. Birrer, Samuel C. Mok

Cancer Res (2010) 70 (8_Supplement): 3298.

DOI: https://doi.org/10.1158/1538-7445.AM10-3298

Published: 15 April 2010

View article

Journal Articles

Abstract 363A: PAX2 is an oncogene in type I ovarian cancer

Huijuan Song, Celestine S. Tung, Yvonne TM Tsang, Samuel C. Mok, David M. Gershenson, Kwong-Kwok Wong

Cancer Res (2010) 70 (8_Supplement): 363A.

DOI: https://doi.org/10.1158/1538-7445.AM10-363A

Published: 15 April 2010

View article

Journal Articles

Antitumor and Antivascular Effects of AVE8062 in Ovarian Carcinoma

Tae Jin Kim, Murali Ravoori, Charles N. Landen, Aparna A. Kamat, Liz Y. Han, Chunhua Lu, Yvonne G. Lin, William M. Merritt, Nicholas Jennings, Whitney A. Spannuth, Robert Langley, David M. Gershenson, Robert L. Coleman, Vikas Kundra, Anil K. Sood

Cancer Res (2007) 67 (19): 9337–9345.

DOI: https://doi.org/10.1158/0008-5472.CAN-06-4018

Published: 01 October 2007

View article

Includes: Supplementary data

Journal Articles

Gene Alterations Identified by Expression Profiling in Tumor-Associated Endothelial Cells from Invasive Ovarian Carcinoma

Chunhua Lu, Tomas Bonome, Yang Li, Aparna A. Kamat, Liz Y. Han, Rosemarie Schmandt, Robert L. Coleman, David M. Gershenson, Robert B. Jaffe, Michael J. Birrer, Anil K. Sood

Cancer Res (2007) 67 (4): 1757–1768.

DOI: https://doi.org/10.1158/0008-5472.CAN-06-3700

Published: 16 February 2007

View article

Includes: Supplementary data

Journal Articles

Metronomic Chemotherapy Enhances the Efficacy of Antivascular Therapy in Ovarian Cancer

Aparna A. Kamat, Tae Jin Kim, Charles N. Landen, Jr., Chunhua Lu, Liz Y. Han, Yvonne G. Lin, William M. Merritt, Premal H. Thaker, David M. Gershenson, Farideh Z. Bischoff, John V. Heymach, Robert B. Jaffe, Robert L. Coleman, Anil K. Sood

Cancer Res (2007) 67 (1): 281–288.

DOI: https://doi.org/10.1158/0008-5472.CAN-06-3282

Published: 08 January 2007

View article

Journal Articles

Antiangiogenic and Antitumor Effects of Src Inhibition in Ovarian Carcinoma

Liz Y. Han, Charles N. Landen, Jose G. Trevino, Jyotsnabaran Halder, Yvonne G. Lin, Aparna A. Kamat, Tae-Jin Kim, William M. Merritt, Robert L. Coleman, David M. Gershenson, William C. Shakespeare, Yihan Wang, Raji Sundaramoorth, Chester A. Metcalf, III, David C. Dalgarno, Tomi K. Sawyer, Gary E. Gallick, Anil K. Sood

Cancer Res (2006) 66 (17): 8633–8639.

DOI: https://doi.org/10.1158/0008-5472.CAN-06-1410

Published: 01 September 2006

View article

Journal Articles

p53 null mutations are highly associated with increased EphA2 expression in ovarian carcinomas

William M. Merritt, Michael T. Deavers, Yvonne G. Lin, Mavis S. Fletcher, Liz Y. Han, Aparna A. Kamat, Charles N. Landen, Jr., Premal H. Thacker, Rosemarie Schmandt, David M. Gershenson, Anil K. Sood

Cancer Res (2006) 66 (8_Supplement): 789–790.

Published: 15 April 2006

View article

Journal Articles

EphA2 overexpression is associated with angiogenesis in ovarian cancer

Yvonne G. Lin, Aparna A. Kamat, Liz Y. Han, William M. Merritt, Premal H. Thaker, Charles N. Landen, Jr., Robert L. Colemen, David M. Gershenson, Michael T. Deavers, Michael S. Kinch, Mavis S. Fletcher, Anil K. Sood

Cancer Res (2006) 66 (8_Supplement): 710.

Published: 15 April 2006

View article

Journal Articles

Circulating cell-free DNA: a novel surrogate biomarker for response to therapy in an ovarian cancer model

Aparna A. Kamat, Farideh Z. Bischoff, Dianne Dang, Liz Han, Charles N. Landen, Jr, Yvonne Lin, William Merritt, David M. Gershenson, Joe L. Simpson, Anil K. Sood

Cancer Res (2006) 66 (8_Supplement): 423.

Published: 15 April 2006

View article

Journal Articles

Expression Profiling of Serous Low Malignant Potential, Low-Grade, and High-Grade Tumors of the Ovary

Tomas Bonome, Ji-Young Lee, Dong-Choon Park, Mike Radonovich, Cindy Pise-Masison, John Brady, Ginger J. Gardner, Ke Hao, Wing H. Wong, J. Carl Barrett, Karen H. Lu, Anil K. Sood, David M. Gershenson, Samuel C. Mok, Michael J. Birrer

Cancer Res (2005) 65 (22): 10602–10612.

DOI: https://doi.org/10.1158/0008-5472.CAN-05-2240

Published: 15 November 2005

View article

Includes: Supplementary data

Journal Articles

Nucleotide excision repair polymorphisms and their role as predictors of clinical outcome in ovarian cancer patients treated with platinum chemotherapy.

Salvador J. Saldivar III, Karen H. Lu, Jian Gu, Maosheng Huang, Anne T. Vladost, David M. Gershenson, Xifeng F. Wu

Cancer Res (2005) 65 (9_Supplement): 115.

Published: 01 May 2005

View article

NARROW

Abstract 3242: The role of SERPINE1 in trametinib resistance in low-grade ovarian serous cancer cell line

Abstract 3985: GDF15 expression level impacts the canonical pathways of the tumor microenvironment and ovarian tumors with wild-type p53 in response to chemotherapy

Abstract CT020: Phase I dose escalation of olaparib (PARP inhibitor) and selumetinib (MEK Inhibitor) combination in solid tumors with Ras pathway alterations

Abstract 135: Immunosuppressive microenvironment in low-grade serous ovarian carcinoma

Abstract CT-05: A phase II trial of selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum

Abstract 2784: Nutlin-3 induces cell cycle arrest in p53 wild-type ovarian carcinomas via upregulation of p21

Abstract 5031: Insulin-like growth factor-1 (IGF-1) is upregulated in low-grade serous ovarian carcinoma

Abstract 4288: Targeted therapy against aldehyde dehydrogenase in ovarian cancer

Abstract 2129A: Clinical implications of infrequent BRAF mutation in advanced stage low-grade ovarian serous carcinomas

Abstract 3298: Elf3 as negative regulation for epithelial-mesenchymal transition in ovarian cancer

Abstract 363A: PAX2 is an oncogene in type I ovarian cancer

Antitumor and Antivascular Effects of AVE8062 in Ovarian Carcinoma

Gene Alterations Identified by Expression Profiling in Tumor-Associated Endothelial Cells from Invasive Ovarian Carcinoma

Metronomic Chemotherapy Enhances the Efficacy of Antivascular Therapy in Ovarian Cancer

Antiangiogenic and Antitumor Effects of Src Inhibition in Ovarian Carcinoma

p53 null mutations are highly associated with increased EphA2 expression in ovarian carcinomas

EphA2 overexpression is associated with angiogenesis in ovarian cancer

Circulating cell-free DNA: a novel surrogate biomarker for response to therapy in an ovarian cancer model

Expression Profiling of Serous Low Malignant Potential, Low-Grade, and High-Grade Tumors of the Ovary

Nucleotide excision repair polymorphisms and their role as predictors of clinical outcome in ovarian cancer patients treated with platinum chemotherapy.

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only